Rev-erbs are members of the nuclear receptor super-family of proteins. They regulate transcription for proteins involved in a number of physiological processes. As such, they represent an attractive drug target. Rev-erb agonists have potential in a number of therapeutic settings, including neurological diseases, autoimmune disorders, and muscular disorders. Currently, there are no modulators of rev-erb on the market.
Researchers at Saint Louis University have developed a new chemical series of rev-erb agonists. They have compiled in vitro and a limited amount of in vivo data to demonstrate the efficacy of these new compounds.
The potential advantages of this technology over existing solutions include:
- Increase pharmocokinetic properties
- Increase potency of therapies
Potential applications of this technology include treating various diseases and disorders such as:
- Neurological diseases, especially those related to anxiety disorders
- Autoimmune disorders
- Muscular disorders
Owner: St. Louis University
IP Protection Status: Pending Patent